

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

Assignment ID: PATI353513

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	I-MAB BIOPHARMA CO., LTD.	03/12/2024
RECEIVING PARTY DATA		
Company Name:	I-MAB BIOPHARMA US LIMITED	
Street Address:	2440 Research Boulevard, Suite 400	
City:	Rockville	
State/Country:	MARYLAND	
Postal Code:	20850	
PROPERTY NUMBERS Total: 5		
Property Type	Number	
Application Number:	17286437	
Application Number:	17683869	
Application Number:	16069144	
Application Number:	16785953	
Application Number:	18270472	
CORRESPONDENCE DATA		
Fax Number:		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	6508152600	
Email:	sdieu@sheppardmullin.com	
Correspondent Name:	SHEPPARD MULLIN RICHTER & HAMPTON LLP	
Address Line 1:	650 Town Center Drive, 10th Floor	
Address Line 4:	Costa Mesa, CALIFORNIA 92626-1993	
ATTORNEY DOCKET NUMBER:	54LW-306090	
NAME OF SUBMITTER:	Steven Dieu	
SIGNATURE:	Steven Dieu	
DATE SIGNED:	07/10/2024	
Total Attachments: 14		
source=IP Assignment Agreement_executed_12Mar2024#page1.tiff		

source=IP Assignment Agreement_executed_12Mar2024#page2.tiff
source=IP Assignment Agreement_executed_12Mar2024#page3.tiff
source=IP Assignment Agreement_executed_12Mar2024#page4.tiff
source=IP Assignment Agreement_executed_12Mar2024#page5.tiff
source=IP Assignment Agreement_executed_12Mar2024#page6.tiff
source=IP Assignment Agreement_executed_12Mar2024#page7.tiff
source=IP Assignment Agreement_executed_12Mar2024#page8.tiff
source=IP Assignment Agreement_executed_12Mar2024#page9.tiff
source=IP Assignment Agreement_executed_12Mar2024#page10.tiff
source=IP Assignment Agreement_executed_12Mar2024#page11.tiff
source=IP Assignment Agreement_executed_12Mar2024#page12.tiff
source=IP Assignment Agreement_executed_12Mar2024#page13.tiff
source=IP Assignment Agreement_executed_12Mar2024#page14.tiff

INTELLECTUAL PROPERTY ASSIGNMENT AGREEMENT

This Intellectual Property Assignment Agreement (this "Agreement") is dated as of March 12, 2024, by and between I-Mab Biopharma Co., Ltd. (in Chinese "天境生物科技(上海)有限公司"), a company organized under the laws of the People's Republic of China ("I-Mab Shanghai"), and I-Mab Biopharma US Limited, a corporation incorporated under the laws of the State of Maryland ("I-Mab US").

WHEREAS, I-Mab Shanghai and I-Mab US have previously entered into that certain Patent and Technology Transfer Framework Agreement dated as of March 9, 2023 (the "Prior Assignment Agreement"), pursuant to which, among other things, I-Mab US has assigned and transferred certain intellectual property assets and rights then owned or held by I-Mab US, including the Assigned Intellectual Property (as defined below), to I-Mab Shanghai in anticipation of a corporate restructuring transaction contemplated among I-Mab Shanghai, I-Mab US and certain of their respective affiliated companies (the "Restructuring");

WHEREAS, it was intended that I-Mab Shanghai should only be assigned and own the intellectual property assets and rights relating to the territory of the Greater China and not any of the Assigned Intellectual Property relating to the territory outside the Greater China, which has been erroneously included in the Prior Assignment Agreement;

WHEREAS, I-Mab Shanghai, I-Mab Biopharma Hong Kong Limited ("I-Mab Hong Kong") and certain other parties have entered into certain transaction agreements consisting of (a) the Equity Transfer Agreement of I-Mab Shanghai, (b) the Equity Transfer Agreement of I-Mab Hangzhou, (c) the Investment Agreement, and (d) the Shareholders' Agreement, each dated as of February 6, 2024 (collectively, the "Restructuring Agreements"), pursuant to which I-Mab Hong Kong will, among other things, sell and transfer all of the equity interests in I-Mab Shanghai and certain other assets and rights to another party as part of the Restructuring; and

WHEREAS, notwithstanding anything to the contrary contained in the Prior Assignment Agreement, and as a condition to the closing of the Restructuring, I-Mab Shanghai agrees to assign and transfer all of its right, title and interests in and to the Assigned Intellectual Property (as defined below) back to I-Mab US, and I-Mab US desires to acquire and take assignment of the Assigned Intellectual Property from I-Mab Shanghai as if the previous assignment and transfer of the Assigned Intellectual Property has not been effected retrospectively and prospectively; and

NOW, THEREFORE, in consideration of the premises and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:

1. Definitions. Capitalized terms used but not otherwise defined herein shall have the meanings set forth in the Restructuring Agreement.

2. Patent Assignment. I-Mab Shanghai hereby irrevocably conveys, assigns, transfers and delivers to I-Mab US and its successors and assigns its entire right, title and interest of every kind in and to (i) each of the patents and patent applications set forth in Schedule I attached hereto under the heading "Scheduled Patents" (the "Scheduled Patents"), (b) patent applications filed under applicable laws in any jurisdiction, including all provisional applications, substitutions, continuations, continuations-in-part, divisions, renewals, and all patents granted thereon; (c) all patents-of-addition, reissues, reexaminations and adjustments, extensions or restorations by existing or future extension or restoration mechanisms, including supplementary protection certificates or the equivalent thereof; (d) inventor's certificates; (e) any other form of government-issued right substantially similar to any of the foregoing; and (f) United States and foreign counterparts (excluding those in Mainland China, Hong Kong, Macau and Taiwan) of any of

the foregoing ((a) through (f) collectively, the "Assigned Patents"), together with all claims and causes of action and all rights to sue or recover and retain damages and costs and attorneys' fees with respect any past, present and future infringement of any Assigned Patent, the same to be held and enjoyed by I-Mab US for its own use and enjoyment and the use and enjoyment of its successors, assigns and other legal representatives as fully and entirely as the same would have been held and enjoyed by I-Mab Shanghai if this assignment had not been made, as I-Mab US of its respective entire right, title and interest therein.

3. Trademark Assignment. I-Mab Shanghai hereby irrevocably conveys, assigns, transfers and delivers to I-Mab US and its successors and assigns its entire right, title and interest of every kind in and to the registered trademarks and trademark applications listed on Schedule II (the "Scheduled Trademarks"), and all issuances, extensions, and renewals thereof, together with the goodwill of the business connected with the use of, and symbolized by the Scheduled Trademarks (collectively, the "Assigned Trademarks" and together with the Assigned Patents, the "Assigned Intellectual Property"), and all claims and causes of action and all rights to sue or recover and retain damages and costs and attorneys' fees with respect any past, present and future infringement of any Assigned Trademark, the same to be held and enjoyed by I-Mab US for its own use and enjoyment and the use and enjoyment of its successors, assigns and other legal representatives as fully and entirely as the same would have been held and enjoyed by I-Mab Shanghai if this assignment had not been made, as I-Mab US of its respective entire right, title and interest therein.

4. Filing and Recordation. The parties hereto agree that I-Mab US may file and record this Agreement or the equivalent of this Agreement with the appropriate governmental authority as necessary to record I-Mab US as the I-Mab US and owner of the Assigned Intellectual Property. I-Mab Shanghai and I-Mab US authorize and request that the United States Patent and Trademark Office, and the corresponding entities or agencies in any applicable foreign jurisdictions, record I-Mab US as the I-Mab US and owner of the Assigned Intellectual Property and issue the patents and register the trademarks from any Assigned Intellectual Property to I-Mab US upon issuance or registration, as applicable.

5. No Third Party Beneficiaries. Nothing contained in this Agreement is intended by the parties to expand the rights and remedies of any third party (other than successors and permitted assigns) against any party hereto as compared to the rights and remedies which such third party would have had against such party had the parties hereto not consummated this Agreement.

6. Successors and Assigns. This Agreement shall be binding upon, insure to the benefit of and be enforceable by I-Mab Shanghai and I-Mab US and their respective successors and assigns, but shall not create any right(s) of subrogation or other right on the part of any other person.

7. Governing Law. This Agreement shall be governed by and construed in accordance with the internal laws of the State of New York, without reference to any conflicts of laws principles.

8. Entire Agreement. This Agreement, together with the Restructuring Agreement and the other documents contemplated hereunder or thereunder, set forth the entire agreement and understanding of the parties hereto with respect to the transactions contemplated hereby and thereby and supersede any and all prior agreements, arrangements and understandings among the parties relating to the subject matter hereof.

9. Severability. Any provision of this Agreement which is prohibited or unenforceable in any jurisdiction shall, as to that jurisdiction, be ineffective to the extent of such prohibition or unenforceability and shall be severed from the balance of this Agreement, all without affecting the remaining provisions of this Agreement or affecting the validity or enforceability of such provision in any other jurisdiction.

10. Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

[Signature Page Follows]

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed and delivered as of the date first above written.

I-Mab Biopharma Co., Ltd.
(天境生物科技(上海)有限公司)



By: _____
Name: Andrew Xuexuan Zhu
Title: Legal Representative

I-Mab Biopharma US Limited

By: _____
Name: Raj Kanna
Title: Sole Director

A handwritten signature in black ink, appearing to read "Raj Kanna", written over a horizontal line.

SCHEDULE I

Project	Title	Territory	Application #
CD4B	ANTI-CLAUDIN 18.2 AND ANTI-4-1BB BISPECIFIC ANTIBODIES AND USES THEREOF	PCT	PCT/CN2020/108707
CD4B	ANTI-CLAUDIN 18.2 AND ANTI-4-1BB BISPECIFIC ANTIBODIES AND USES THEREOF	Australia	2020329466
CD4B	ANTI-CLAUDIN 18.2 AND ANTI-4-1BB BISPECIFIC ANTIBODIES AND USES THEREOF	Brazil	BR112021008870-9
CD4B	ANTI-CLAUDIN 18.2 AND ANTI-4-1BB BISPECIFIC ANTIBODIES AND USES THEREOF	Canada	3117740
CD4B	ANTI-CLAUDIN 18.2 AND ANTI-4-1BB BISPECIFIC ANTIBODIES AND USES THEREOF	Chile	202101375
CD4B	ANTI-CLAUDIN 18.2 AND ANTI-4-1BB BISPECIFIC ANTIBODIES AND USES THEREOF	Colombia	NC2021/0006953
CD4B	ANTI-CLAUDIN 18.2 AND ANTI-4-1BB BISPECIFIC ANTIBODIES AND USES THEREOF	Eurasia	202190838
CD4B	ANTI-CLAUDIN 18.2 AND ANTI-4-1BB BISPECIFIC ANTIBODIES AND USES THEREOF	EPO	20851985.0
CD4B	ANTI-CLAUDIN 18.2 AND ANTI-4-1BB BISPECIFIC ANTIBODIES AND USES THEREOF	Indonesia	P00202105183
CD4B	ANTI-CLAUDIN 18.2 AND ANTI-4-1BB BISPECIFIC ANTIBODIES AND USES THEREOF	Israel	283379
CD4B	ANTI-CLAUDIN 18.2 AND ANTI-4-1BB BISPECIFIC ANTIBODIES AND USES THEREOF	India	202117020591
CD4B	ANTI-CLAUDIN 18.2 AND ANTI-4-1BB BISPECIFIC ANTIBODIES AND USES THEREOF	Japan	2021-522496
CD4B	ANTI-CLAUDIN 18.2 AND ANTI-4-1BB BISPECIFIC ANTIBODIES AND USES THEREOF	Japan	2023-184798
CD4B	ANTI-CLAUDIN 18.2 AND ANTI-4-1BB BISPECIFIC ANTIBODIES AND USES THEREOF	Korea	10-2021-7015572
CD4B	ANTI-CLAUDIN 18.2 AND ANTI-4-1BB BISPECIFIC ANTIBODIES AND USES THEREOF	Mexico	MX/a/2021/006428
CD4B	ANTI-CLAUDIN 18.2 AND ANTI-4-1BB BISPECIFIC ANTIBODIES AND USES THEREOF	Malaysia	PI2021002811

Project	Title	Territory	Application #
CD4B	ANTI-CLAUDIN 18.2 AND ANTI-4-1BB BISPECIFIC ANTIBODIES AND USES THEREOF	New Zealand	775277
CD4B	ANTI-CLAUDIN 18.2 AND ANTI-4-1BB BISPECIFIC ANTIBODIES AND USES THEREOF	Peru	000768-2021/DIN
CD4B	ANTI-CLAUDIN 18.2 AND ANTI-4-1BB BISPECIFIC ANTIBODIES AND USES THEREOF	Philippines	1-2021-551269
CD4B	ANTI-CLAUDIN 18.2 AND ANTI-4-1BB BISPECIFIC ANTIBODIES AND USES THEREOF	Singapore	11202104131V
CD4B	ANTI-CLAUDIN 18.2 AND ANTI-4-1BB BISPECIFIC ANTIBODIES AND USES THEREOF	Ukraine	a2021 02064
CD4B	ANTI-CLAUDIN 18.2 AND ANTI-4-1BB BISPECIFIC ANTIBODIES AND USES THEREOF	USA	17/286,437
CD4B	ANTI-CLAUDIN 18.2 AND ANTI-4-1BB BISPECIFIC ANTIBODIES AND USES THEREOF	USA	17/683,869
CD4B	ANTI-CLAUDIN 18.2 AND ANTI-4-1BB BISPECIFIC ANTIBODIES AND USES THEREOF	South Africa	2021/03174
CD4B Dosage	A METHOD OF TREATING SOLID TUMOR	PCT	PCT/CN2023/095544
CD4B Combo	COMBINATION OF ANTI-CLAUDIN 18.2/4-1BB BISPECIFIC ANTIBODIES AND A SECOND THERAPEUTIC AGENT IN THE TREATMENT OF CANCER	PCT priority	PCT/CN2023/122092
L14B	ANTI-PD-L1/ANTI-4-1BB BISPECIFIC ANTIBODIES AND USES THEREOF	PCT	PCT/CN2019/075180
L14B	ANTI-PD-L1/ANTI-4-1BB BISPECIFIC ANTIBODIES AND USES THEREOF	Australia	AU 2019390274
L14B	ANTI-PD-L1/ANTI-4-1BB BISPECIFIC ANTIBODIES AND USES THEREOF	Brazil	BR112021010402-0
L14B	ANTI-PD-L1/ANTI-4-1BB BISPECIFIC ANTIBODIES AND USES THEREOF	Canada	CA3121562
L14B	ANTI-PD-L1/ANTI-4-1BB BISPECIFIC ANTIBODIES AND USES THEREOF	Chile	202101368
L14B	ANTI-PD-L1/ANTI-4-1BB BISPECIFIC ANTIBODIES AND USES THEREOF	Colombia	NC2021/0006911
L14B	ANTI-PD-L1/ANTI-4-1BB BISPECIFIC ANTIBODIES AND USES THEREOF	EPO	19890398.1
L14B	ANTI-PD-L1/ANTI-4-1BB BISPECIFIC ANTIBODIES AND USES THEREOF	Eurasia	EA202191457
L14B	ANTI-PD-L1/ANTI-4-1BB BISPECIFIC ANTIBODIES AND USES THEREOF	Indonesia	P00202104749
L14B	ANTI-PD-L1/ANTI-4-1BB BISPECIFIC ANTIBODIES AND USES THEREOF	Israel	IL283530
L14B	ANTI-PD-L1/ANTI-4-1BB BISPECIFIC ANTIBODIES AND USES THEREOF	India	202147028629
L14B	ANTI-PD-L1/ANTI-4-1BB BISPECIFIC ANTIBODIES AND USES THEREOF	Japan	2021-531379

Project	Title	Territory	Application #
L14B	ANTI-PD-L1/ANTI-4-1BB BISPECIFIC ANTIBODIES AND USES THEREOF	Korea	10-2021-7020162
L14B	ANTI-PD-L1/ANTI-4-1BB BISPECIFIC ANTIBODIES AND USES THEREOF	Mexico	MX/a/2021/006379
L14B	ANTI-PD-L1/ANTI-4-1BB BISPECIFIC ANTIBODIES AND USES THEREOF	Malaysia	PI2021002924
L14B	ANTI-PD-L1/ANTI-4-1BB BISPECIFIC ANTIBODIES AND USES THEREOF	New Zealand	775540
L14B	ANTI-PD-L1/ANTI-4-1BB BISPECIFIC ANTIBODIES AND USES THEREOF	Peru	774-2021
L14B	ANTI-PD-L1/ANTI-4-1BB BISPECIFIC ANTIBODIES AND USES THEREOF	Philippines	1-2021-551171
L14B	ANTI-PD-L1/ANTI-4-1BB BISPECIFIC ANTIBODIES AND USES THEREOF	Singapore	SG11202105152Y
L14B	ANTI-PD-L1/ANTI-4-1BB BISPECIFIC ANTIBODIES AND USES THEREOF	Ukraine	a202103192
L14B	ANTI-PD-L1/ANTI-4-1BB BISPECIFIC ANTIBODIES AND USES THEREOF	USA	17/298,741
L14B	ANTI-PD-L1/ANTI-4-1BB BISPECIFIC ANTIBODIES AND USES THEREOF	South Africa	2021/02870
L14B dosage	METHODS OF TREATING CANCER BY ADMINISTERING ANTI PD-L1/ANTI-4-1BB BISPECIFIC ANTIBODIES	provisional	KR 10-2023-0068303
L14B dosage	METHODS OF TREATING CANCER BY ADMINISTERING ANTI PD-L1/ANTI-4-1BB BISPECIFIC ANTIBODIES	provisional	KR 10-2023-0122323
L14B dosage	METHODS OF TREATING CANCER BY ADMINISTERING ANTI PD-L1/ANTI-4-1BB BISPECIFIC ANTIBODIES	provisional	KR 10-2024-0003030
L14B dosage	Combo Treatment	provisional	KR 10-2023-0120984
D5	ANTI-CD73 ANTIBODIES AND USES THEREOF	PCT	PCT/CN2018/073746
D5	ANTI-CD73 ANTIBODIES AND USES THEREOF	Austria	18733153.3
D5	ANTI-CD73 ANTIBODIES AND USES THEREOF	Australia	2018213549
D5	ANTI-CD73 ANTIBODIES AND USES THEREOF	Australia	2022202847
D5	ANTI-CD73 ANTIBODIES AND USES THEREOF	Belgium	18733153.3
D5	ANTI-CD73 ANTIBODIES AND USES THEREOF	Brazil	BR112019012040-8
D5	ANTI-CD73 ANTIBODIES AND USES THEREOF	Canada	3,045,376
D5	ANTI-CD73 ANTIBODIES AND USES THEREOF	Switzerland	18733153.3
D5	ANTI-CD73 ANTIBODIES AND USES THEREOF	Chile	201901756
D5	ANTI-CD73 ANTIBODIES AND USES THEREOF	Colombia	NC2019/0006657
D5	ANTI-CD73 ANTIBODIES AND USES THEREOF	Czechia	18733153.3
D5	ANTI-CD73 ANTIBODIES AND USES THEREOF	Germany	18733153.3

Project	Title	Territory	Application #
D5	ANTI-CD73 ANTIBODIES AND USES THEREOF	Denmark	18733153.3
D5	ANTI-CD73 ANTIBODIES AND USES THEREOF	Eurasia	201991099
D5	ANTI-CD73 ANTIBODIES AND USES THEREOF	EPO	18733153.3
D5	ANTI-CD73 ANTIBODIES AND USES THEREOF	EPO	22150866.6
D5	ANTI-CD73 ANTIBODIES AND USES THEREOF	Spain	18733153.3
D5	ANTI-CD73 ANTIBODIES AND USES THEREOF	Finland	18733153.3
D5	ANTI-CD73 ANTIBODIES AND USES THEREOF	France	18733153.3
D5	ANTI-CD73 ANTIBODIES AND USES THEREOF	United Kingdom	18733153.3
D5	ANTI-CD73 ANTIBODIES AND USES THEREOF	Greece	18733153.3
D5	ANTI-CD73 ANTIBODIES AND USES THEREOF	Croatia	18733153.3
D5	ANTI-CD73 ANTIBODIES AND USES THEREOF	Hungary	18733153.3
D5	ANTI-CD73 ANTIBODIES AND USES THEREOF	Indonesia	PID201905985
D5	ANTI-CD73 ANTIBODIES AND USES THEREOF	Ireland	18733153.3
D5	ANTI-CD73 ANTIBODIES AND USES THEREOF	Israel	267942
D5	ANTI-CD73 ANTIBODIES AND USES THEREOF	Israel	290842
D5	ANTI-CD73 ANTIBODIES AND USES THEREOF	India	201917021878
D5	ANTI-CD73 ANTIBODIES AND USES THEREOF	Iceland	18733153.3
D5	ANTI-CD73 ANTIBODIES AND USES THEREOF	Italy	18733153.3
D5	ANTI-CD73 ANTIBODIES AND USES THEREOF	Japan	2019-528825
D5	ANTI-CD73 ANTIBODIES AND USES THEREOF	Korea	10-2019-7025714
D5	ANTI-CD73 ANTIBODIES AND USES THEREOF	Korea	10-2020-7026020
D5	ANTI-CD73 ANTIBODIES AND USES THEREOF	Lithuania	18733153.3
D5	ANTI-CD73 ANTIBODIES AND USES THEREOF	Luxembourg	18733153.3
D5	ANTI-CD73 ANTIBODIES AND USES THEREOF	Latvia	18733153.3
D5	ANTI-CD73 ANTIBODIES AND USES THEREOF	Monaco	18733153.3
D5	ANTI-CD73 ANTIBODIES AND USES THEREOF	Malta	18733153.3
D5	ANTI-CD73 ANTIBODIES AND USES THEREOF	Mexico	MX/a/2019/008758
D5	ANTI-CD73 ANTIBODIES AND USES THEREOF	Malaysia	PI2019003100

Project	Title	Territory	Application #
D5	ANTI-CD73 ANTIBODIES AND USES THEREOF	Netherlands	18733153.3
D5	ANTI-CD73 ANTIBODIES AND USES THEREOF	Norway	18733153.3
D5	ANTI-CD73 ANTIBODIES AND USES THEREOF	New Zealand	753714
D5	ANTI-CD73 ANTIBODIES AND USES THEREOF	Peru	001312-2019/DIN
D5	ANTI-CD73 ANTIBODIES AND USES THEREOF	Philippines	1-2019-550087
D5	ANTI-CD73 ANTIBODIES AND USES THEREOF	Poland	18733153.3
D5	ANTI-CD73 ANTIBODIES AND USES THEREOF	Portugal	18733153.3
D5	ANTI-CD73 ANTIBODIES AND USES THEREOF	Romania	18733153.3
D5	ANTI-CD73 ANTIBODIES AND USES THEREOF	Russia	201991099
D5	ANTI-CD73 ANTIBODIES AND USES THEREOF	Serbia	18733153.3
D5	ANTI-CD73 ANTIBODIES AND USES THEREOF	Sweden	18733153.3
D5	ANTI-CD73 ANTIBODIES AND USES THEREOF	Singapore	11201904495S
D5	ANTI-CD73 ANTIBODIES AND USES THEREOF	Slovenia	18733153.3
D5	ANTI-CD73 ANTIBODIES AND USES THEREOF	Slovakia	18733153.3
D5	ANTI-CD73 ANTIBODIES AND USES THEREOF	Turkey	18733153.3
D5	ANTI-CD73 ANTIBODIES AND USES THEREOF	Ukraine	a201906244
D5	ANTI-CD73 ANTIBODIES AND USES THEREOF	USA	16/069,144
D5	ANTI-CD73 ANTIBODIES AND USES THEREOF	USA	16/785,953
D5	ANTI-CD73 ANTIBODIES AND USES THEREOF	South Africa	2019/04619
D5	FORMULATIONS OF ANTI-CD73 ANTIBODIES	PCT	PCT/CN2021/092485
D5	FORMULATIONS OF ANTI-CD73 ANTIBODIES	Canada	3203441
D5	FORMULATIONS OF ANTI-CD73 ANTIBODIES	USA	?
D5	FORMULATIONS OF ANTI-CD73 ANTIBODIES	Japan	2023-540516
D5	FORMULATIONS OF ANTI-CD73 ANTIBODIES	Australia	2021415180
D5	FORMULATIONS OF ANTI-CD73 ANTIBODIES	Russia	2023116656
D5	FORMULATIONS OF ANTI-CD73 ANTIBODIES	Korea	10-2023-7025806
D5	FORMULATIONS OF ANTI-CD73 ANTIBODIES	EPO	21912814.7
Biomarker	BIOMARKERS AND METHODS FOR TREATING NSCLC	PCT	PCT/CN2023/096557



Project	Title	Territory	Application #
D5 Dosage Regimen	A METHOD OF TREATING SOLID TUMOR	PCT	PCT/CN2023/096583
D5 Dosage Regimen	A METHOD OF TREATING SOLID TUMOR	PCT	PCT/US2023/067548
C4	NOVEL CD47 MONOCLONAL ANTIBODIES AND USES THEREOF	Australia	2021203783
C4	NOVEL CD47 MONOCLONAL ANTIBODIES AND USES THEREOF	Australia	2017332960
C4	NOVEL CD47 MONOCLONAL ANTIBODIES AND USES THEREOF	Canada	2,999,058
C4	NOVEL CD47 MONOCLONAL ANTIBODIES AND USES THEREOF	Eurasia	201990764
C4	NOVEL CD47 MONOCLONAL ANTIBODIES AND USES THEREOF	EPO	22182052.5
C4	PHARMACEUTICAL COMPOSITIONS CONTAINING ANTI-CD47 ANTIBODIES	EPO	21796475.8
C4	NOVEL ANTI-CD47 ANTIBODIES AND USES THEREOF	EPO	21879507.8
C4	METHODS FOR MITIGATING INTERFERENCE BY THERAPEUTIC ANTI-CD47 ANTIBODIES IN PRE-TRANSFUSION ASSAYS	EPO	21879508.6
C4	NOVEL CD47 MONOCLONAL ANTIBODIES AND USES THEREOF	Japan	2022-035942
C4	NOVEL CD47 MONOCLONAL ANTIBODIES AND USES THEREOF	Japan	2023-060732
C4	NOVEL CD47 MONOCLONAL ANTIBODIES AND USES THEREOF	Japan	2018-519859
C4	PHARMACEUTICAL COMPOSITIONS CONTAINING ANTI-CD47 ANTIBODIES	Japan	2022-565654
C4	NOVEL ANTI-CD47 ANTIBODIES AND USES THEREOF	Japan	2023-547735
C4	NOVEL CD47 MONOCLONAL ANTIBODIES AND USES THEREOF	Korea	10-2020-7020714
C4	NOVEL CD47 MONOCLONAL ANTIBODIES AND USES THEREOF	Korea	10-2018-7010559
C4	NOVEL CD47 MONOCLONAL ANTIBODIES AND USES THEREOF	USA	16/989,702
C4	PHARMACEUTICAL COMPOSITIONS CONTAINING ANTI-CD47 ANTIBODIES	USA	17/997,522
C4	NOVEL ANTI-CD47 ANTIBODIES AND USES THEREOF	USA	18/249,054
C4	METHODS FOR MITIGATING INTERFERENCE BY THERAPEUTIC ANTI-CD47 ANTIBODIES IN PRE-TRANSFUSION ASSAYS	USA	18/031,858
C4	COMBINATION THERAPIES COMPRISING A KRAS INHIBITOR FOR THE TREATMENT OF CANCER	PCT	PCT/CN2022/079307
C4	COMBINATION THERAPIES COMPRISING A KRAS INHIBITOR FOR THE TREATMENT OF CANCER	PCT	PCT/CN2023/079640

Project	Title	Territory	Application #
C4	COMBINATION THERAPIES COMPRISING AN ANTI-HER2 ANTIBODY-DRUG CONJUGATE FOR THE TREATMENT OF CANCER	PCT	PCT/CN2022/084432
C4	COMBINATION THERAPIES COMPRISING AN ANTI-HER2 ANTIBODY-DRUG CONJUGATE FOR THE TREATMENT OF CANCER	PCT	PCT/CN2023/085380
C4	NOVEL ANTI-CD47 ANTIBODIES AND USES THEREOF	PCT	PCT/CN2023/137414

PATENT

REEL: 067953 FRAME: 0860

SCHEDULE II

No.	Trademark	Jurisdiction	Class	Registration No.	Status	Register Date	Validity
1		CN	1	42124223	Granted	2020/11/7	2030/11/6
2			9	42123094	Granted	2020/11/7	2030/11/6
3		US	5	6143195	Granted	2020/9/1	/
4		CN	1	42108751	Granted	2020/11/7	2030/11/6
5			9	42107116	Granted	2020/11/7	2030/11/6
6		US	5	6143200	Granted	2020/9/1	/
7		CN	1	43837658	Granted	2021/5/28	2031/5/27
8			9	43819853	Granted	2021/5/21	2031/5/20
9			35	43825654	Granted	2021/9/21	2031/9/20
10			40	43811877	Granted	2021/10/28	2031/10/27
11			42	43837838	Granted	2021/11/14	2031/11/13
12		US	5	6629613	Granted	2022/1/25	/
13			42				
14		CN	1	43831837	Granted	2021/5/21	2031/5/20
15			40	43811874	Granted	2021/10/28	2031/10/27
16			42	43813035	Granted	2022/10/7	2032/10/6
17		US	5	6852814	Granted	2022/9/20	/
18		CN	5	61829318	Pending	/	/
19		HK	5	304567005	Granted	2018/6/19	2028/6/18
			10				
			35				
			42				
			5				
			10	304567014	Granted	2018/6/19	2028/6/18
			35				

No.	Trademark	Jurisdiction	Class	Registration No.	Status	Register Date	Validity
20	I-MAB	CN	42				
21			1	32296292	Granted	2019/9/28	2029/9/27
22			5	42941036	Granted	2020/9/21	2030/9/20
23			9	43151440	Granted	2020/8/28	2030/8/27
24			30	53639262	Granted	2021/9/21	2031/9/20
25			35	32311592	Granted	2019/9/28	2029/9/27
26			40	32401466	Granted	2019/6/7	2029/6/6
27			42	32304522	Granted	2019/10/7	2029/10/6
28			2	53625017	Granted	2021/9/21	2031/9/20
29			3	53631685	Granted	2021/9/21	2031/9/20
30			4	53639592	Granted	2021/9/28	2031/9/27
31			7	53625172	Granted	2021/9/28	2031/9/27
32			8	53644388	Granted	2021/9/21	2031/9/20
33			10	53629884	Granted	2021/9/21	2031/9/20
34			11	53625213	Granted	2021/9/21	2031/9/20
35			12	53647193	Granted	2021/9/21	2031/9/20
36			13	53632069	Granted	2021/9/21	2031/9/20
37			14	53647304	Granted	2021/9/21	2031/9/20
38			15	53642271	Granted	2021/9/21	2031/9/20
39			16	53630022	Granted	2021/9/21	2031/9/20
40			17	53647930	Granted	2021/9/21	2031/9/20
41			18	53632117	Granted	2021/9/21	2031/9/20
42			19	53630041	Granted	2021/9/21	2031/9/20
43			20	53639239	Granted	2021/9/28	2031/9/27
44			21	53642317	Granted	2021/10/28	2031/10/27
45			22	53639249	Granted	2021/9/21	2031/9/20
46			23	53634510	Granted	2021/9/21	2031/9/20
47			24	53651078	Granted	2021/9/21	2031/9/20
48			25	53647098	Granted	2021/9/28	2031/9/27
49			26	53637923	Granted	2021/9/21	2031/9/20
50			28	53629305	Granted	2021/9/21	2031/9/20
			29	53642331	Granted	2021/9/21	2031/9/20

PATENT

REEL: 067953 FRAME: 0862

No.	Trademark	Jurisdiction	Class	Registration No.	Status	Register Date	Validity
51			31	53642337	Granted	2021/9/21	2031/9/20
52			32	53651096	Granted	2021/9/21	2031/9/20
53			33	53638380	Granted	2021/9/21	2031/9/20
54			34	53634279	Granted	2021/9/21	2031/9/20
55			36	53629937	Granted	2021/9/21	2031/9/20
56			37	53626809	Granted	2021/9/21	2031/9/20
57			38	53645902	Granted	2021/9/21	2031/9/20
58			39	53629332	Granted	2021/9/21	2031/9/20
59			41	53626815	Granted	2021/9/21	2031/9/20
60			43	53634290	Granted	2021/9/21	2031/9/20
61			44	53648251	Granted	2021/9/28	2031/9/27
62			45	53645783	Granted	2021/9/21	2031/9/20
63			5	6615802	Granted	2022/1/11	/
64		US	42	6629594	Granted	2022/1/25	/
65	I-MAB Biopharma	CN	1	32296301	Granted	2019/10/7	2029/10/6
66			35	32304499	Granted	2019/9/28	2029/9/27
67			40	32401465	Granted	2019/6/7	2029/6/6
68			42	32289653	Granted	2019/9/28	2029/9/27

PATENT

REEL: 067953 FRAME: 0863

RECORDED: 07/10/2024